Eli Lilly and Company $LLY Shares Purchased by Sage Advisors LLC

by · The Cerbat Gem

Sage Advisors LLC increased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,974 shares of the company’s stock after purchasing an additional 270 shares during the quarter. Eli Lilly and Company makes up 10.6% of Sage Advisors LLC’s portfolio, making the stock its 3rd biggest position. Sage Advisors LLC’s holdings in Eli Lilly and Company were worth $14,791,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Brighton Jones LLC increased its position in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC increased its position in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd grew its position in shares of Eli Lilly and Company by 24.9% during the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after buying an additional 85 shares during the period. GAMMA Investing LLC grew its position in shares of Eli Lilly and Company by 25.8% during the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock worth $14,866,000 after buying an additional 3,696 shares during the period. Finally, Warner Financial Inc. grew its position in shares of Eli Lilly and Company by 129.2% during the 1st quarter. Warner Financial Inc. now owns 1,123 shares of the company’s stock worth $927,000 after buying an additional 633 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LLY. Cantor Fitzgerald set a $925.00 target price on Eli Lilly and Company and gave the stock an “overweight” rating in a research report on Thursday. Berenberg Bank restated a “hold” rating and set a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. HSBC boosted their target price on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Finally, DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $948.06.

Check Out Our Latest Stock Report on LLY

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 1.8%

NYSE:LLY opened at $818.60 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a market capitalization of $774.77 billion, a PE ratio of 53.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The business’s 50-day simple moving average is $743.43 and its 200-day simple moving average is $765.54.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the business posted $3.92 EPS. Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).